9236 Results of PX-171–003-A0, part 1 of an open-label, single-arm, phase 2 study of carfilzomib in patients with relapsed and refractory multiple myeloma

D. Siegel; R. Vij; K. Stewart; G. Somlo; A. Jakubowiak; V. Kukreti; N. Bahlis; S. Singhal; A. Wong; S. Jagannath

doi:10.1016/s1359-6349(09)71927-5

9236 Results of PX-171–003-A0, part 1 of an open-label, single-arm, phase 2 study of carfilzomib in patients with relapsed and refractory multiple myeloma

European Journal of Cancer Supplements ◽

10.1016/s1359-6349(09)71927-5 ◽

2009 ◽

Vol 7 (2) ◽

pp. 571 ◽

Cited By ~ 1

Author(s):

D. Siegel ◽

R. Vij ◽

K. Stewart ◽

G. Somlo ◽

A. Jakubowiak ◽

...

Keyword(s):

Multiple Myeloma ◽

Phase 2 ◽

Open Label ◽

Refractory Multiple Myeloma ◽

Phase 2 Study

Get full-text (via PubEx)

Belantamab mafodotin for relapsed or refractory multiple myeloma (DREAMM-2): a two-arm, randomised, open-label, phase 2 study

The Lancet Oncology ◽

10.1016/s1470-2045(19)30788-0 ◽

2020 ◽

Vol 21 (2) ◽

pp. 207-221 ◽

Cited By ~ 72

Author(s):

Sagar Lonial ◽

Hans C Lee ◽

Ashraf Badros ◽

Suzanne Trudel ◽

Ajay K Nooka ◽

...

Keyword(s):

Multiple Myeloma ◽

Phase 2 ◽

Open Label ◽

Refractory Multiple Myeloma ◽

Phase 2 Study ◽

Open Label Phase

Get full-text (via PubEx)

A multicenter, open-label, phase 2 study of lenalidomide plus low-dose dexamethasone in Chinese patients with relapsed/refractory multiple myeloma: the MM-021 trial

Journal of Hematology & Oncology ◽

10.1186/1756-8722-6-41 ◽

2013 ◽

Vol 6 (1) ◽

Cited By ~ 24

Author(s):

Jian Hou ◽

Xin Du ◽

Jie Jin ◽

Zhen Cai ◽

Fangping Chen ◽

...

Keyword(s):

Multiple Myeloma ◽

Low Dose ◽

Chinese Patients ◽

Phase 2 ◽

Open Label ◽

Refractory Multiple Myeloma ◽

Phase 2 Study ◽

Open Label Phase

Get full-text (via PubEx)

Subcutaneous Daratumumab Plus Carfilzomib and Dexamethasone (D-Kd) in Relapsed/Refractory Multiple Myeloma: An Open-label, Multicenter, Phase 2 Study (PLEIADES)

Clinical Lymphoma Myeloma & Leukemia ◽

10.1016/j.clml.2019.09.240 ◽

2019 ◽

Vol 19 (10) ◽

pp. e144

Author(s):

Ajai Chari ◽

Hartmut Goldschmidt ◽

shiyi yang ◽

Michele Kosh ◽

Maria Delioukina ◽

...

Keyword(s):

Multiple Myeloma ◽

Phase 2 ◽

Open Label ◽

Refractory Multiple Myeloma ◽

Multicenter Phase ◽

Phase 2 Study

Get full-text (via PubEx)

13 / An Open-label Phase 2 Study of Carfilzomib plus Dexamethasone to Assess Tolerability and Adherence in Patients with Relapsed or Refractory Multiple Myeloma at US Community Oncology Centers

10.26226/morressier.5b3b802db1b87b000eceda02 ◽

2018 ◽

Author(s):

Fonseca Rafael

Keyword(s):

Multiple Myeloma ◽

Phase 2 ◽

Open Label ◽

Refractory Multiple Myeloma ◽

Community Oncology ◽

Phase 2 Study ◽

Open Label Phase

Get full-text (via PubEx)

An Open-Label Phase 2 Study of Carfilzomib plus Dexamethasone to Assess Tolerability and Adherence in Patients with Relapsed or Refractory Multiple Myeloma at US Community Oncology Centers

Clinical Lymphoma Myeloma & Leukemia ◽

10.1016/j.clml.2018.07.131 ◽

2018 ◽

Vol 18 ◽

pp. S240-S241

Author(s):

Rafael Fonseca ◽

Melissa Alsina ◽

Jesus Berdeja ◽

Stephen B. Heitner ◽

Christopher Morris ◽

...

Keyword(s):

Multiple Myeloma ◽

Phase 2 ◽

Open Label ◽

Refractory Multiple Myeloma ◽

Community Oncology ◽

Phase 2 Study ◽

Open Label Phase

Get full-text (via PubEx)

An open-label, single-arm, phase 2 study of single-agent carfilzomib in patients with relapsed and/or refractory multiple myeloma who have been previously treated with bortezomib

British Journal of Haematology ◽

10.1111/j.1365-2141.2012.09232.x ◽

2012 ◽

Vol 158 (6) ◽

pp. 739-748 ◽

Cited By ~ 122

Author(s):

Ravi Vij ◽

David S. Siegel ◽

Sundar Jagannath ◽

Andrzej J. Jakubowiak ◽

Alexander Keith Stewart ◽

...

Keyword(s):

Multiple Myeloma ◽

Single Agent ◽

Phase 2 ◽

Open Label ◽

Refractory Multiple Myeloma ◽

Phase 2 Study ◽

Previously Treated

Get full-text (via PubEx)

Multicenter Open Label Phase 2 Study of Isatuximab Plus Pomalidomide and Dexamethasone With Carfilzomib in Relapsed or Refractory Multiple Myeloma

Case Medical Research ◽

10.31525/ct1-nct04287855 ◽

2020 ◽

Author(s):

Keyword(s):

Multiple Myeloma ◽

Phase 2 ◽

Open Label ◽

Refractory Multiple Myeloma ◽

Phase 2 Study ◽

Open Label Phase

Get full-text (via PubEx)

Efficacy and safety of oral panobinostat plus subcutaneous bortezomib and oral dexamethasone in patients with relapsed or relapsed and refractory multiple myeloma (PANORAMA 3): an open-label, randomised, phase 2 study

The Lancet Oncology ◽

10.1016/s1470-2045(20)30680-x ◽

2021 ◽

Vol 22 (1) ◽

pp. 142-154

Author(s):

Jacob P Laubach ◽

Fredrik Schjesvold ◽

Mário Mariz ◽

Meletios A Dimopoulos ◽

Ewa Lech-Maranda ◽

...

Keyword(s):

Multiple Myeloma ◽

Phase 2 ◽

Efficacy And Safety ◽

Open Label ◽

Refractory Multiple Myeloma ◽

Oral Dexamethasone ◽

Phase 2 Study

Get full-text (via PubEx)

Initial Results of MCRN 009: Phase 2 Study of an Accelerated Infusion Rate of Daratumumab in Patients with Relapsed/Refractory Multiple Myeloma (MM).

Clinical Lymphoma Myeloma & Leukemia ◽

10.1016/j.clml.2019.09.428 ◽

2019 ◽

Vol 19 (10) ◽

pp. e259

Author(s):

Julie Stakiw ◽

Vishal Kukreti ◽

Richard LeBlanc ◽

Michael Sebag ◽

Annette Hay ◽

...

Keyword(s):

Multiple Myeloma ◽

Infusion Rate ◽

Phase 2 ◽

Refractory Multiple Myeloma ◽

Phase 2 Study ◽

Initial Results

Get full-text (via PubEx)

Updated results of a phase 2 study of panobinostat combined with melphalan, thalidomide and prednisone (MPT) in relapsed/refractory multiple myeloma

Leukemia & Lymphoma ◽

10.1080/10428194.2017.1372575 ◽

2017 ◽

Vol 59 (5) ◽

pp. 1271-1273 ◽

Cited By ~ 3

Author(s):

Massimo Offidani ◽

Laura Corvatta ◽

Anna Marina Liberati ◽

Stefano Pulini ◽

Stelvio Ballanti ◽

...

Keyword(s):

Multiple Myeloma ◽

Phase 2 ◽

Refractory Multiple Myeloma ◽

Phase 2 Study

Get full-text (via PubEx)